Lupus Nephritis from Pathogenesis to New Therapies: An Update. (PubMed, Int J Mol Sci) - Sep 1, 2024 - "This review aims to provide a comprehensive update on progress on several key aspects in this setting: pathogenetic mechanisms of LN, including new insight into the role of autoantibodies, complement, vitamin D deficiency, and interaction between infiltrating immune cells and kidney resident ones; the evolving role of renal biopsy and biomarkers, which may integrate information from renal histology; newly approved drugs such as voclosporin (VOC) and belimumab (BEL), allowing a more articulate strategy for induction therapy, and other promising phase III-immunosuppressive (IS) agents in the pipeline. Integrating these therapeutic areas requires an effort towards a holistic and multidisciplinary approach. At the same time, the availability of an increasingly wider armamentarium may translate into improvements in patient's renal outcomes over the next decades."
Biomarker • Journal • Review • Cardiovascular • Chronic Kidney Disease • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease • Systemic Lupus Erythematosus
|
|
Alessia Francese; Annalisa Roveta; Antonio G Maconi; Brigida Brezzi; Emanuele Luigi Parodi; Francesca Tunesi; Guido Merlotti; Marco Quaglia; Valentina Zanetti
|